Real-world outcomes of two different sensor-augmented insulin pumps with predictive low glucose suspend function in type 1 diabetes patients

Aim: To analyse the real-life outcomes of two sensor-augmented pumps (SAP) with predictive low glucose suspend (PLGS) function, Medtronic Minimed 640G (TM) with SmartGuard (MM640G) and Tandem T Slim X2 (TM) with Basal-IQ (TM) (TTSX2), in Type 1 Diabetes Mellitus (T1DM) patients. Methods: Observational cross-sectional study using data obtained from computerized clinical records. All T1DM patients on TTSX2 therapy were compared (1:1) with MM640G treated patients selected through stratified sampling. Primary efficacy outcome was to describe time in rage (TIR, 70-180 mg/dL, 3.9-10 mmol/L) interstitial glucose differences according to a non-inferiority hypothesis with TTSX2 compared to MM640G. Results: Forty-four patients were analyzed (female 66%). Mean age was 38.9 yrs. (range 23-59 yrs.) and mean diabetes duration was 23.4 +/- 9.2 yrs. Patients treated with TTSX2 showed a numerically slightly lower, but non-statistically significantly different, TIR from the MM640G pump group (64.9 +/- 16.4% vs. 72.4 +/- 17.0%, P = 0.108). Similarly, we did no find differences in HbA1c between T1D patients treated with TTSX2 and MM640G (6.8 +/- 1.0% vs. 7.0 +/- 0.9%, 51 +/- 11 mmol/mol vs. 53 +/- 10 mmol/mol, P = 0.312). Moreover, rest of evaluated glycemic outcomes were similar between both treatment groups. Conclusions: Patients using two different SAP with PLGS automatic function showed similar glycaemic control in a real-world scenario. (C) 2021 Elsevier B.V. All rights reserved.